Likarda receives $4M to expand companion animal diabetes researchThe company aims for a minimally invasive, cost-effective solution for pet owners September 4, 2017 Likarda, a regenerative medicine company for companion animals, has received $4 million in Series A funding from Werth Family Investment Associates to back the company’s proprietary Kanslet insulin-producing cell clusters, which can be infused into animals with diabetes, allowing veterinarians to offer a minimally invasive and cost-effective answer to pet owners, according to the company. Microencapsulated islets (the insulin-producing cells of the body) are transplanted via injection into the belly of a diabetic dog, removing the need for twice-daily insulin injections, the company stated. The additional funding allows Likarda to scale the project to thousands of animals, and the clinical research program is expected to launch by the end of 2017. “Partnership with Werth Family Investment Associates brings both funds to advance our product line and extensive experience in successful pharmaceutical licensing of new products for both human and animal health,” said Lisa Stehno-Bittel, Ph.D., Likarda president and co-founder. “[It’s] exciting and transformational for both animal health in the region and the global prospect of cell-based therapies for diabetic pets.”
SponsoredThe search for a non-insulin alternative is over.Be the first to know about Bexacat! + Learn More
Suggested Veterinary Products DR Wizard 2.0High Quality Images• Direct deposited Cesium Iodide• 5 year hardware and software warranty• Wireless lightweight 14” x 17” detector panel is very...Client Engagement & Communication ServicesIs telephone congestion pulling your people away from doing their best work? Do you often have clients on hold or voicemail boxes that are full? Do you have...
SponsoredFeline urinary health—meet a simple solutionUrinary health is complicated, but the solution doesn’t have to be. Our products nutritionally support urinary tract and bladder health at any stage. + Recommend Today